CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调控 CAR 转基因表达以设计半自主 CAR-T
英文原题：Regulation of CAR transgene expression to design semiautonomous CAR-T.
查看英文原题
Regulation of CAR transgene expression to design semiautonomous CAR-T.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
有效的转基因表达对于基因工程细胞治疗至关重要。因此，无论是已注册产品还是下一代方法，CAR-T 细胞治疗的关键关注领域之一都是转基因的表达。事实证明，临床产品中使用的各种组成型启动子可能影响CAR-T 细胞的抗肿瘤效果并影响生产过程。此外，下一代CAR-T 开始安装远程控制诱导型启动子甚至自主表达系统，开辟了启动、增强和提高CAR-T 安全性的新途径。在本文中，广泛的组成型和诱导型启动子已被分组和结构化，使得可以比较它们的优缺点以及临床使用情况。最后，基于Synthetic Notch的logic gates已被详细阐述，展示了所需外部信号与基因工程细胞反应的耦合。
展开英文摘要原文
Effective transgene expression is critical for genetically engineered cell therapy.
Therefore, one of CAR-T cell therapy's critical areas of interest, both in registered products and next-generation approaches is the expression of transgenes. It turns out that various constitutive promoters used in clinical products may influence CAR-T cell antitumor effectiveness and impact the manufacturing process.
Furthermore, next-generation CAR-T starts to install remotely controlled inducible promoters or even autonomous expression systems, opening new ways of priming, boosting, and increasing the safety of CAR-T. In this article, a wide range of constitutive and inducible promoters has been grouped and structured, making it possible to compare their pros and cons as well as clinical usage.
Finally, logic gates based on Synthetic Notch have been elaborated, demonstrating the coupling of desired external signals with genetically engineered cellular responses.
论文信息
- 作者
- Głowacki P、Tręda C、Rieske P
- 单位
- Department of Tumor Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 Street, 90-752 Lodz, Poland.Poland
- 文献类型
- 综述
- 期刊
- Molecular therapy. Oncology2024 Sep 19
- 原文标识
- PubMed 39184876 · DOI 10.1016/j.omton.2024.200833
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →